

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation of the mixture FLOVENT HFA

Registration number -

Synonyms FLOVENT HFA INHALATION AEROSOL * FLIXOTIDE AEROSOL 134A * FLIXOTIDE INHALER CFC FREE * FLIXOTIDE EVOHALER * ATEMUR MITE INHALER HFA 134A 50 MCG * ATEMUR MITE INHALER HFA 134A 125 MCG * ATEMUR FORTE INHALER HFA 134A 250 MCG * AXOTIDE INHALER HFA * BREXOVENT INHALER HFA * FLUTIDE MITE 50 DOSIER-AEROSOL * FLUTIDE 125 DOSIER-AEROSOL FCKW-FREI * FLUTIDE FORTE 250 DOSIER-AEROSOL FCKW-FREI * FLIXOTAIDE INHALER HFA * NDC NO: 0173-0718-20 * NDC NO: 0173-0719-20 * NDC NO: 0173-0720-20 * FLUTICASONE PROPIONATE, FORMULATED PRODUCT

Issue date 21-October-2014

Version number 18

Revision date 21-October-2014

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product.

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient. Medicinal Product

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information (normal business hours): +44-20-8047-5000
Email Address: msds@gsk.com
Website: www.gsk.com

1.4. Emergency telephone number

TRANSPORT EMERGENCIES::
UK In-country toll call: +(44)-870-8200418
International toll call: +1 703 527 3887
available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.3. Other hazards Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.
Aerosol containers may violently rupture when exposed to the heat of fire.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
---------------	---	------------------	------------------------	-----------	-------

1,1,1,2-TETRAFLUOROETHANE	99.66 - 99.91	811-97-2 212-377-0	-	-	
Classification:	DSD: - CLP: -				
FLUTICASONE PROPIONATE	0.09< 0.34	80474-14-2 -	-	-	
Classification:	DSD: Repr. Cat. 2;R61, Repr. Cat. 3;R62, Xn;R22-48/20/21 CLP: Acute Tox. 4;H302, Repr. 1B;H360D, Repr. 2;H361f, STOT RE 2;H373				

List of abbreviations and symbols that may be used above

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information

In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. The need for pre-placement and periodic health surveillance must be determined by risk assessment. Following assessment, if the risk of exposure is considered significant then exposed individuals should receive health surveillance focused on detecting skin conditions.

In the event of overexposure, individuals should receive post-exposure health surveillance focused on detecting skin conditions and adrenal suppression.

4.1. Description of first aid measures

Inhalation	If breathing is difficult, trained personnel should give oxygen. Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin contact	Immediately flush with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Take off contaminated clothing and wash before reuse. Get medical attention if symptoms occur.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
Ingestion	If swallowed, rinse mouth with water (only if the person is conscious). Never give anything by mouth to a victim who is unconscious or is having convulsions. Get medical advice/attention if you feel unwell.

4.2. Most important symptoms and effects, both acute and delayed

The following adverse effects have been noted with therapeutic use of this material: increased susceptibility to infection; headache; drying of the nasal passages; Irritation of nose and throat.

4.3. Indication of any immediate medical attention and special treatment needed

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

SECTION 5: Firefighting measures

General fire hazards

Aerosol containers may violently rupture when exposed to the heat of fire.

5.1. Extinguishing media

Suitable extinguishing media	Water. Foam. Dry chemical powder. Carbon dioxide (CO ₂).
Unsuitable extinguishing media	None known.

5.2. Special hazards arising from the substance or mixture

During fire, gases hazardous to health may be formed. Pressurised container may explode when exposed to heat or flame.

5.3. Advice for firefighters

Special protective equipment for firefighters	Self-contained breathing apparatus and full protective clothing must be worn in case of fire.
Special fire fighting procedures	Move containers from fire area if you can do so without risk.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear appropriate protective equipment and clothing during clean-up. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

6.2. Environmental precautions Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Do not contaminate water. Avoid discharge into drains, water courses or onto the ground. Inform appropriate managerial or supervisory personnel of all environmental releases.

6.3. Methods and material for containment and cleaning up Prevent product from entering drains. Following product recovery, flush area with water.

Never return spills to original containers for re-use.

6.4. Reference to other sections For personal protection, see section 8. For waste disposal, see section 13 of the SDS.

SECTION 7: Handling and storage

7.1. Precautions for safe handling Avoid prolonged exposure. Do not taste or swallow. When using, do not eat, drink or smoke. Provide adequate ventilation. Wear appropriate personal protective equipment. Wash hands thoroughly after handling. Avoid release to the environment. Do not empty into drains. Observe good industrial hygiene practices.

7.2. Conditions for safe storage, including any incompatibilities The pressure in sealed containers can increase under the influence of heat. Keep away from heat and flame. Store in a cool, dry place out of direct sunlight. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS). The recommended temperature for storage is 15 - 25 °C.

7.3. Specific end use(s) Medicinal Product.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK Components	Type	Value	Note
FLUTICASONE PROPIONATE (CAS 80474-14-2)	8 HR TWA	3 mcg/m3	
	OHC	4	skin
		4	Reproductive hazard

Biological limit values No biological exposure limits noted for the ingredient(s).

Recommended monitoring procedures Follow standard monitoring procedures.

Derived no-effect level (DNEL) Not available.

Predicted no effect concentrations (PNECs) Not available.

Exposure guidelines

8.2. Exposure controls

Appropriate engineering controls An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. General ventilation normally adequate.

Individual protection measures, such as personal protective equipment

General information Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.

Eye/face protection Not normally needed. If contact is likely, safety glasses with side shields are recommended. (e.g. EN 166).

Skin protection

- Hand protection	Not normally needed. For prolonged or repeated skin contact use suitable protective gloves. Select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time).
- Other	Not normally needed. Wear suitable protective clothing as protection against splashing or contamination. (EN 14605 for splashes, EN ISO 13982 for dust).
Respiratory protection	No personal respiratory protective equipment normally required. When workers are facing concentrations above the exposure limit they must use appropriate certified respirators. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic, inorganic, acid inorganic, alkaline compounds and toxic particles (eg. EN 14387).
Thermal hazards	Wear appropriate thermal protective clothing, when necessary.
Hygiene measures	Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional.
Environmental exposure controls	
Hazard guidance and control recommendations	Contain spills and prevent releases and observe national regulations on emissions. Inform appropriate managerial or supervisory personnel of all environmental releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state	Liquid.
Form	Aerosol
Colour	Not available.
Odour	Not available.
Odour threshold	Not available.
pH	Not available.
Melting point/freezing point	Not available.
Initial boiling point and boiling range	-26 °C (-14.8 °F)
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Not available.
Solubility (other)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Explosive properties	Not available.
Oxidizing properties	Not available.
9.2. Other information	No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
10.2. Chemical stability	Material is stable under normal conditions.

10.3. Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
10.4. Conditions to avoid	Contact with incompatible materials. Avoid direct sunlight, conditions that might generate heat and sources of ignition.
10.5. Incompatible materials	Strong oxidising agents.
10.6. Hazardous decomposition products	Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

SECTION 11: Toxicological information

General information	Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause adverse effects.
Information on likely routes of exposure	
Inhalation	Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin contact	Pharmacological effects might occur following direct contact with skin. Repeated contact may increase sensitivity of skin to bruising.
Eye contact	May be irritating to eyes.
Ingestion	Health injuries are not known or expected under normal use. However, ingestion is not likely to be a primary route of occupational exposure. Harmful if swallowed.
Symptoms	The following adverse effects have been noted with therapeutic use of this material: increased susceptibility to infection; headache; drying of the nasal passages; Irritation of nose and throat.

11.1. Information on toxicological effects

Acute toxicity	Harmful if swallowed. May be harmful in contact with skin.
-----------------------	--

Components	Species	Test results
1,1,1,2-TETRAFLUOROETHANE (CAS 811-97-2)		
Acute		
<i>Inhalation</i>		
LCL0	Rat	567000 ppm, 4 hour
LOEC	Rat	200000 mg/day CNS depression.
Subchronic		
<i>Inhalation</i>		
NOAEC	Rat	50000 ppm, 13 weeks
FLUTICASONE PROPIONATE (CAS 80474-14-2)		
Acute		
<i>Oral</i>		
LD50	Rat	> 1000 mg/kg
Subacute		
<i>Inhalation</i>		
NOAEL	Rat	0.2 mcg/L/day, 28 Day
Subchronic		
<i>Inhalation</i>		
LOEL	Rat	3 mcg/kg/day, 26 weeks
NOAEL	Dog	68 mcg/kg/day, 26 weeks
	Rat	14 mcg/kg/day, 26 weeks

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation	Repeated contact may increase sensitivity of skin to bruising.
----------------------------------	--

Corrosivity

FLUTICASONE PROPIONATE	OECD 404 Result: negative
------------------------	------------------------------

Irritation Corrosion - Skin: P.I.I. value

FLUTICASONE PROPIONATE	0
------------------------	---

Serious eye damage/eye irritation	May be irritating to eyes.
--	----------------------------

Eye

FLUTICASONE PROPIONATE	OECD 405 Result: negative Species: Rabbit
------------------------	---

Respiratory sensitisation	None known.
----------------------------------	-------------

Skin sensitisation	Allergic skin reactions might occur following repeated contact with this material in susceptible individuals.	
Sensitisation		
FLUTICASONE PROPIONATE		0 % OECD 406 Result: negative Species: Guinea pig
Germ cell mutagenicity	No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.	
Mutagenicity		
1,1,1,2-TETRAFLUOROETHANE		Ames Result: negative
FLUTICASONE PROPIONATE		Ames Result: negative Bacterial High Throughput Fluctuation Test Result: negative Chinese Hamster Ovarian Cell Test Result: negative Chromosomal Aberration Assay In Vivo Result: negative Dominant lethal assay, Inhalation study. Result: negative Species: Rat In vivo cytogenetics Result: negative Micronucleus Assay Result: negative Species: Mouse Micronucleus Test Result: negative Species: Mouse SOS/umu Assay Result: negative
1,1,1,2-TETRAFLUOROETHANE		Unscheduled DNA Synthesis in vivo, Inhalation study. Result: negative Species: Rat
FLUTICASONE PROPIONATE		Yeast Result: negative
Carcinogenicity	Carcinogenic effects are not expected as a result of occupational exposure. Not classifiable as to carcinogenicity to humans.	
1,1,1,2-TETRAFLUOROETHANE		2500 - 5000 ppm Inhalation Result: negative Species: Rat Test Duration: 2 years 5000 ppm Inhalation Result: negative Species: Rat Test Duration: 78 weeks
FLUTICASONE PROPIONATE		Inhalation Result: negative Species: Rat dermal Result: negative Species: Mouse oral Result: negative Species: Mouse
Reproductive toxicity	Components in this product have been shown to cause birth defects and reproductive disorders in laboratory animals.	
Reproductivity		
FLUTICASONE PROPIONATE		100 mcg/kg/day Embryofetal Development Result: reduced foetal bodyweight, minor skeletal variations Species: Rat 100 mcg/kg/day Female fertility (Segment I) Result: reduced foetal bodyweight, minor skeletal variations Species: Rat
1,1,1,2-TETRAFLUOROETHANE		40000 ppm Foetal development - inhalation Result: Maternal toxicity; Foetal NOAEL Species: Rabbit
FLUTICASONE PROPIONATE		50 mcg/kg/day Pre- and Post-natal development Result: maternal toxicity Species: Rat

Reproductivity

1,1,1,2-TETRAFLUOROETHANE

50000 ppm Foetal development - inhalation
Result: Maternal toxicity, delayed foetal development.

Species: Rat

FLUTICASONE PROPIONATE

>= 25.7 mcg/kg/day Embryofetal Development

Result: maternal toxicity, reduced foetal body weight; no malformations or other variations

Species: Rat

>= 45 mcg/kg/day Embryofetal Development

Result: cleft palate

Species: Mouse

>= 50 mcg/kg/day Embryofetal Development

Result: maternal toxicity; reduced foetal weight; foetal resorptions

Species: Rabbit

SAR / QSAR, Glucocorticoid

Specific target organ toxicity - single exposure None known.

1,1,1,2-TETRAFLUOROETHANE

Species: Dog

Organ: Heart

Specific target organ toxicity - repeated exposure May cause damage to organs through prolonged or repeated exposure. Adrenal glands. Bone tissue. Immune system.

Aspiration hazard Not established. Not likely, due to the form of the product.

Mixture versus substance information No information available.

Other information Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause adverse effects.

1,1,1,2-TETRAFLUOROETHANE

0, Asphyxiant

SECTION 12: Ecological information

12.1. Toxicity No information is available about the potential of this material to produce adverse environmental effects. Contains a substance which causes risk of hazardous effects to the environment.

Components	Species	Test results
FLUTICASONE PROPIONATE (CAS 80474-14-2)		
<i>Acute</i>		
	IC50	Activated sludge
		> 1000 mg/l, 3 hours
Aquatic		
<i>Acute</i>		
Crustacea	EC50	Water flea (Daphnia magna)
		> 0.55 mg/l, 48 hours Static test
Terrestrial		
<i>Acute</i>		
Earthworm	EC50	Manure worm (Eisenia foetida)
		> 1000 mg/kg, 28 days

* Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability

Hydrolysis

Half-life (Hydrolysis-neutral)

FLUTICASONE PROPIONATE

> 1 years Measured

Biodegradability

Percent degradation (Aerobic biodegradation-ready)

FLUTICASONE PROPIONATE

< 44 %, 28 days

Percent degradation (Aerobic biodegradation-soil)

FLUTICASONE PROPIONATE

9 - 50 %, 64 days

12.3. Bioaccumulative potential

Partition coefficient

n-octanol/water (log Kow)

1,1,1,2-TETRAFLUOROETHANE

1.274

FLUTICASONE PROPIONATE

2.78

12.4. Mobility in soil

Adsorption

Sludge/biomass distribution coefficient - log Kd

FLUTICASONE PROPIONATE

3.13 - 3.55 Estimated

Adsorption**Soil/sediment sorption - log K_{oc}**

FLUTICASONE PROPIONATE

3.41 - 3.83 Measured

Mobility in general Not available.**12.5. Results of PBT and vPvB assessment** Not available.**12.6. Other adverse effects** Not available.**SECTION 13: Disposal considerations****13.1. Waste treatment methods**

Residual waste	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.
EU waste code	The Waste code should be assigned in discussion between the user, the producer and the waste disposal company.
Disposal methods/information	Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Dispose in accordance with all applicable regulations.
Special precautions	Dispose in accordance with all applicable regulations.

SECTION 14: Transport information**ADR**

14.1. UN number	UN1950
14.2. UN proper shipping name	AEROSOLS, asphyxiant
14.3. Transport hazard class(es)	
Class	2.2
Subsidiary risk	-
Label(s)	2.2
Hazard No. (ADR)	Not available.
Tunnel code	E
14.4. Packing group	Not applicable.
14.5. Environmental hazards	No.
14.6. Special precautions for user	Not available.

IATA

14.1. UN number	UN1950
14.2. UN proper shipping name	Aerosols, non-flammable
14.3. Transport hazard class(es)	2.2
Subsidiary class(es)	-
14.4. Packing group	Not available.
14.5. Environmental hazards	No.
Labels required	2.2
ERG Code	2L
14.6. Special precautions for user	Not available.

Other information**Cargo aircraft only** Allowed.**Additional Information:****Passenger & cargo** Allowed.**IMDG**

14.1. UN number	UN1950
14.2. UN proper shipping name	AEROSOLS, asphyxiant
14.3. Transport hazard class(es)	
Class	2
Subsidiary risk	5A
Label(s)	2.2
14.4. Packing group	Not applicable.

14.5. Environmental hazards

Marine pollutant

No.

EmS

Not available.

14.6. Special precautions
for user

Not available.

14.7. Transport in bulk
according to Annex II of
MARPOL73/78 and the IBC Code

MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

ADR; IATA



General information

Classifications are for the material when offered for transport as fully regulated. Depending on the specific transport details (Ship-From/Ship To locations, quantities being shipped, type of packaging and mode of transport) it may be possible to ship this material in a manner other than fully regulated. (One example is IATA Limited or Excepted Quantity. There are others.) Be sure to review all regulatory agency packaging instructions and special provisions, referenced in this section, to identify options applicable to the specifics of your shipment.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations

The product is classified and labelled in accordance with EC directives or respective national laws. This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations

Follow national regulation for work with chemical agents.

15.2. Chemical safety assessment

No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations

Not available.

References

GSK Hazard Determination

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.

Full text of any statements or R-phrases and H-statements under Sections 2 to 15

R22 Harmful if swallowed.
R48/20/21 Harmful: danger of serious damage to health by prolonged exposure through inhalation and in contact with skin.
R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
R61 May cause harm to the unborn child.
R62 Possible risk of impaired fertility.
H302 Harmful if swallowed.
H360D May damage the unborn child.
H361f Suspected of damaging fertility.
H373 May cause damage to organs through prolonged or repeated exposure.

Revision information

Product and Company Identification: Product and Company Identification
Composition / Information on Ingredients: Ingredients
Physical & Chemical Properties:
Ecological Information: Mobility
Transport information:
Regulatory Information: United States
GHS: Classification

Training information

Follow training instructions when handling this material.

Disclaimer

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.